Trials / Unknown
UnknownNCT04686643
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 306 (estimated)
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A phase 3 study to evaluate efficacy and safety of AGSAVI
Detailed description
A randomized, double-blind, multicenter, phase 3 study to evaluate efficacy and safety of AGSAVI for Inadequately Controlled with AGLS
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGSAVI | S-amlodipine, Valsartan, Indapamide |
| DRUG | AGLS | S-amlodipine, Valsartan |
Timeline
- Start date
- 2021-02-01
- Primary completion
- 2022-02-01
- Completion
- 2022-05-01
- First posted
- 2020-12-29
- Last updated
- 2020-12-29
Source: ClinicalTrials.gov record NCT04686643. Inclusion in this directory is not an endorsement.